INSL3 and congenital adrenal hyperplasia: Accordingly, it could be speculated that INSL3 is a new candidate in the management of male patients with CAH, and therefore, the present study was commenced on the initiative of the European Reference Network on Rare Endocrine Conditions (https://endo-ern.eu/).